Moreover, we compared the prevalence of PD-L1 expression between the following pairs: age <60 years and age ≥60 years (two comparisons), Gleason score <7 and Gleason score ≥7 groups (five comparisons), pathologic stage pT2 and pathologic stage pT3-pT4 groups (five comparisons), lymph node metastasis N0 and N1 (four comparisons), PSA level ≤10 ng/ml and PSA level >10 ng/ml (two comparisons), and androgen receptor-positive and androgen receptor-negative (two comparisons). This evidence concerns the gene AR and metastatic malignant neoplasm in the lymph nodes.